Abstract
We have read with interest the article by Stradella et al., suggesting ERCC3 as a new gene predisposing the hereditary breast (BC) and ovarian (OC) cancer. The authors identified 13 ERCC3 mutation carriers among 1311 patients with hereditary breast and/or ovarian cancer (HBOC; 0.99%), while the mutation burden in Spanish controls was four times lower (0.22%) and corresponded to European non-Finnish GnomAD controls (0.24%).
The authors found a significant association of ERCC3 mutations with OC risk. This was surprising for us as we observed no such association in our previous study analysing 1333 OC patients.